Evidence map›Paper›PMID 24710824›Full record

ArticlePathology oncology research : POR2014

Frequency of genetic and epigenetic alterations of p14ARF and p16INK4A in head and neck cancer in a Hungarian population.

Andrea Kis, Tímea Zsófia Tatár, Tamás Gáll, Róbert Boda, Ildikó Tar, Tamás Major, Pál Redl, Lajos Gergely, Krisztina Szarka

Abstract read
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. BioMed research international · 2017
    Article
  6. Oncology letters · 2016
    Article
  7. P15 gene methylation in hepatocellular carcinomas: a systematic review and meta-analysis.International journal of clinical and experimental medicine · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Andrea KisDepartment of Medical Microbiology, Faculty of Medicine, University of Debrecen, H-4032, Debrecen, Nagyerdei krt. 98, Hungary.
Tímea Zsófia Tatár
Tamás Gáll
Róbert Boda
Ildikó Tar
Tamás Major
Pál Redl
Lajos Gergely
Krisztina Szarka

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Occurrence of genetic and epigenetic alterations affecting p14ARF and p16INK4A were investigated in tumour samples of 37 oral (OSCC) and 28 laryngeal squamous cell cancer (LSCC) patients, and compared to exfoliated buccal epithelial cells of 68 healthy controls. Presence of deletions and mutations/polymorphisms affecting exons were examined using sequencing. Methylation status of promoters was assessed by methylation-specific PCR. Chi-square and Fisher's exact tests were used to compare frequency of events. Exon deletions were found in four controls, one OSCC and 22 LSCC patients; the latter significantly differed from controls (p < 0.001). Only two mutations (T24610A and C24702A) were in p16 exon 1 of two OSCC patients. Polymorphisms G28575A (Ala140Thr), G31292C (C540G) and G28608A were found in both patient groups. The p14 promoter was unmethylated in 86.7 % of OSCC and in 85.7 % of LSCC patients; for the p16 promoter these rates were 69.0 % and 76.2 % for OSCC and LSCC patients, respectively. Combining the two patient groups, unmethylated promoter was significantly less frequent in case of both p14 and p16 (p = 0.043 and p = 0.001, respectively) compared to the control group. In summary, exon deletion may be important in LSCC, while promoter methylation was relatively frequent in both patient groups.

Indexed as

Gene DeletionAdultAgedCarcinoma, Squamous CellCase-Control StudiesCyclin-Dependent Kinase Inhibitor p16DNA MethylationEpigenesis, GeneticFemaleFollow-Up StudiesGene SilencingHumansHungaryLaryngeal NeoplasmsMaleMiddle AgedCyclin-Dependent Kinase Inhibitor p16Tumor Suppressor Protein p14ARF

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.